Drug Trial Radar · NCT00168792
A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)
Last checked: Nov 20, 2026Latest source record: Oct 29, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,671
Actual
Start
Nov 2003
Primary completion
Jul 2006
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- Collaborators
- Genentech, Inc.
- First posted
- Sep 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute myocardial infarcts as compared to primary PCI alone.
Conditions
- Myocardial Infarction
Interventions
TenecteplaseDrug
PCIProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Death or cardiogenic shock or congestive heart failure within 90 daysTime frame: 90 days
Locations
176 sites in 18 countries. Site status is shown where the registry gives one.
Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
Boehringer Ingelheim Investigational Site
Fort Lauderdale, Florida
Boehringer Ingelheim Investigational Site
St. Petersburg, Florida
Boehringer Ingelheim Investigational Site
Tampa, Florida
Boehringer Ingelheim Investigational Site
Macan, Georgia
Boehringer Ingelheim Investigational Site
Detroit, Michigan
Boehringer Ingelheim Investigational Site
Omaha, Nebraska
Boehringer Ingelheim Investigational Site
Providence, Rhode Island
Boehringer Ingelheim Investigational Site
Feldkirch, Austria
Boehringer Ingelheim Investigational Site
Sankt Pölten, Austria
Boehringer Ingelheim Investigational Site
Vienna, Austria
Boehringer Ingelheim Investigational Site
Wiener Neustadt, Austria
Boehringer Ingelheim Investigational Site
Aalst, Belgium
Boehringer Ingelheim Investigational Site
Anderlecht, Belgium
Boehringer Ingelheim Investigational Site
Angleur, Belgium
Boehringer Ingelheim Investigational Site
Antwerp, Belgium
Boehringer Ingelheim Investigational Site
Bonheiden, Belgium
Boehringer Ingelheim Investigational Site
Bouge, Belgium
Boehringer Ingelheim Investigational Site
Bruges, Belgium
Boehringer Ingelheim Investigational Site
Brussels, Belgium
Boehringer Ingelheim Investigational Site
Charleroi, Belgium
Boehringer Ingelheim Investigational Site
Genk, Belgium
Boehringer Ingelheim Investigational Site
Ghent, Belgium
Boehringer Ingelheim Investigational Site
Gilly, Belgium
Boehringer Ingelheim Investigational Site
Huy, Belgium
Boehringer Ingelheim Investigational Site
La Louvière, Belgium
Boehringer Ingelheim Investigational Site
Leuven, Belgium
Boehringer Ingelheim Investigational Site
Liège, Belgium
Boehringer Ingelheim Investigational Site
Namur, Belgium
Boehringer Ingelheim Investigational Site
Roeselare, Belgium
Boehringer Ingelheim Investigational Site
Blumenau - SC, Brazil
Boehringer Ingelheim Investigational Site
Curitiba - PR, Brazil
Boehringer Ingelheim Investigational Site
Marília - SP, Brazil
Boehringer Ingelheim Investigational Site
Passo Fundo - RS, Brazil
Boehringer Ingelheim Investigational Site
Porto Alegre - RS, Brazil
Boehringer Ingelheim Investigational Site
São Paulo - SP, Brazil
Boehringer Ingelheim Investigational Site
Victoria, British Columbia, Canada
Boehringer Ingelheim Investigational Site
Greater Sudbury, Ontario, Canada
Boehringer Ingelheim Investigational Site
Saint-Foy, Ontario, Canada
Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
Showing 40 of 176 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.